Future perspectives on malignant melanoma

Surgical Clinics of North America

Volumn 83, Issue 2, 2003, Pages 453-456

  Leong, Stanley P L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CANVAXIN; INTERFERON; VASCULOTROPIN C;

CANCER IMMUNOTHERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; EARLY DIAGNOSIS; EXCISION; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0037397148     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(02)00204-9     Document Type: Review

References (16)

1. Ramirez R, Schneider J. Practical guide to sun protection. Surg Clin North Am 2003;83:97-107.
2. Swetter SM. Dermatological perspectives of malignant melanoma. Surg Clin North Am 2003;83:77-95.
3. Reintgen D, Balch CM, Kirkwood J, et al. Recent advances in the care of the patient with malignant melanoma. Ann Surg 1997;225:1-14.
4. Leong SPL. Selective sentinel lymphadenectomy for malignant melanoma. Surg Clin North Am 2003;83:157-85.
5. Wang E, Miller LD, Ohnmacht GA, et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002;62:3581-6.
6. Johnson DS, Yamane S, Morita S, et al. Malignant melanoma in non-Caucasians: experience from Hawaii. Surg Clin North Am 2003;83:357-64.
7. Brown C, Kirkwood JM. Medical management of melanoma. Surg Clin North Am 2003;83:201-39.
8. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
9. Kirkwood JM, Ibrahim J, Sondak V, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial. J Clin Oncol 2000;18:2444-58.
10. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
11. Kadison AS, Morton DL. Immunotherapy of malignant melanoma. Surg Clin North Am 2003;83:261-88.
12. Halaban R, von Willebrand MC. Signal transduction abnormalities as therapeutic targets. In: Borden EC, editor. Melanoma: biologically targeted therapeutics. Totowa (NJ): Humana Press; 2002. p. 287-323.
13. Anand-Apte B, Fox PL. Tumor angiogenesis. In: Borden EC, editor. Melanoma: biologically targeted therapeutics. Totowa (NJ): Humana Press; 2002. p. 325-60.
14. Parker VP. Antiangiogenic therapy for melanoma. In: Borden EC, editor. Melanoma: biologically targeted therapeutics. Totowa (NJ): Humana Press; 2002. p. 361-77.
15. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883-6.
16. Gershenwald JE, Fidler IJ. Cancer. Targeting lymphatic metastasis. Science 2002;296:1811-1812.